Articles tagged with Cancer
A pilot study of the Participant Engagement Portal (PEP) tool shows that 84% of participants had a positive experience, with high usability and satisfaction rates. PEP facilitates two-way communication between patients and clinicians, allowing for self-reporting of social risk factors and future research opportunities.
Researchers investigated polyisoprenylated cysteinyl amide inhibitors (PCAIs) for their anticancer effects on pancreatic cancer cells with KRAS mutations. The compounds demonstrated strong activity against cell survival, migration, and invasion pathways. PCAI treatment caused hyperactivation of MAPK and PI3K/AKT pathways, leading to ox...
A new UCLA study reveals that creatine supplementation significantly slows tumor growth in mice by fueling dendritic cells, a critical class of immune cells. The findings suggest that creatine may be used to enhance the immune response of patients receiving immunotherapy or improve the quality of dendritic cell-based vaccines.
Research in flies shows that tumor cells with chromosomal instability can become senescent and release signals altering neighboring tissue behavior. This process promotes tumor growth by inducing the death of nearby healthy cells.
Researchers used patient-derived xenograft (PDX) models to study deadly DNA loops in cancer cells. They found significant similarities between human tumor samples and PDX models, including consistent presence of extra copies of oncogenes. These findings suggest that ecDNA-positive tumor cells may drive tumor growth and recurrence.
Researchers found that glandular and squamous cancer cells share a common origin but diverge early in tumor development. This discovery challenges the long-standing debate over whether each cancer subtype originates from distinct cells or a single multipotent cell.
A UCF researcher is investigating how probiotics can treat damage from acid reflux disease, which affects one-fourth of Americans and increases the risk for esophageal cancer. Early results show a reduction in Barrett's esophagus and delayed cancer development.
Researchers developed a new platform to visualize drug-tumor interactions, allowing them to measure drug delivery and signaling in human solid tumors. This approach revealed pronounced spatial heterogeneity in drug delivery and target engagement across different tumor types.
Researchers developed multifunctional metal–organic framework nanoparticles that degrade HK-2, suppress glycolysis, and induce cuproptosis. CHNDs showed stronger anticancer activity than either the HK-2 degrader or the copper nanoplatform alone, disrupting protein homeostasis and cancer energy metabolism.
A novel deep learning framework integrates high-resolution pathology images with spatial transcriptomics and proteomics to reveal complex intra-tumor heterogeneity in colorectal cancer. The approach identifies distinct molecular subtypes that correlate with immune cell infiltration patterns.
Researchers analyzed data from over 50,000 adults who started taking aspirin and found a similar bladder cancer prevalence but lower invasive stage. Aspirin initiators received more cystoscopies, which uncovered the cancer. The study suggests that aspirin may unmask otherwise asymptomatic bladder cancer.
The center is the first in the region to offer TCR-T therapy, an FDA-approved treatment targeting proteins inside cancer cells. Patients with chemotherapy-resistant synovial sarcoma can now access this novel cellular therapy.
Researchers at UMass Amherst have designed a new therapy that combines engineered Salmonella bacteria with oncolytic viruses to target liver and pancreatic cancer. The treatment showed promising results in animal models, leading to significant tumor reduction and improved survival rates.
UCLA researchers are developing an AI-enhanced imaging platform to improve yttrium-90 radioembolization planning for patients with liver cancer. The new approach uses dynamic contrast-enhanced MRI scans to better characterize tumor blood flow and predict microsphere distribution.
A new study has found that cancers with shrunken genomes are more widespread than previously thought, often associated with highly unstable tumours. Researchers developed a method to distinguish between two leukaemias based on recurring chromosome patterns, offering important clinical insights for patient treatment decisions.
The study provides new insight into how cells recognize and remove harmful DNA bases using human SMUG1 enzyme. The enzyme removes uracil and related damaged bases from DNA to prevent permanent mutations.
Researchers used an open-source AI model called Mirai to quickly identify high-risk patients and expedite their diagnostic process. This led to a significant reduction in wait times, with some women receiving biopsy results within days of having their mammograms done.
A multicenter clinical trial found that adding aglatimagene besadenovec to standard radiation therapy improved disease-free survival for intermediate- and high-risk localized prostate cancer patients. The treatment reduced the risk of recurrence by 27% compared to the placebo group.
The foundation has awarded fellowships to Minsoo Kim, Sahana Kuthyar, and Matthew Leventhal to investigate rare cell populations in healthy tissues and pneumonia risk in immunocompromised patients. They aim to develop new computational tools to understand biomarkers and microenvironmental influences.
Dr. Mina Sedrak has been selected to co-lead the Cancer in the Older Adult Committee of The Alliance for Clinical Trials in Oncology, focusing on improving care and outcomes for older adults with cancer. As a leading expert on aging and cancer, Sedrak aims to expand research on this population and address their unique needs.
A recent study published in Science Direct found that patients with detectable circulating tumor DNA (ctDNA) benefit from chemotherapy, with a three-year relapse-free survival rate of 77 percent. The test can help identify patients who require more targeted treatment, potentially reducing the risk of recurrence.
Researchers identified microRNA-25 as a key player in creating an immune-suppressive tumor environment that resists cancer immunotherapy. Removing miR-25 reshaped the environment and activated anti-tumor immune responses, suggesting a potential target for converting 'cold' tumors into responsive 'hot' tumors.
Researchers at Stevens Institute of Technology discover that mature gut cells can revert to cancer-driving stem cells, explaining why colorectal cancers are resistant to treatment. This finding suggests pathways for effective therapies and sheds light on the complex cellular environment of the intestines.
Researchers found that 66.6% of gene expression changes are linked to e-cigarette flavor and device type, while only 28.8% relate to vaping frequency or amount. The study suggests that each flavor has unique biological effects.
A randomized clinical trial found that an app-facilitated palliative care intervention maintained health-related quality of life and reduced acute care use. This digital self-management approach also boosted patient self-efficacy.
The study found high-risk associations between alcohol use and all ten cancers examined, with risk increasing progressively as intake rose. Low-to-moderate drinking was associated with lower disease risk for type 2 diabetes, Alzheimer's disease, ischemic heart disease, and stroke.
New research suggests that megamitochondria initially protect hepatocytes during early alcohol exposure, but later contribute to inflammation and liver cancer progression. The study proposes a 'dual-phase' model, highlighting the importance of mitochondrial dynamics in regulating metabolism and innate immunity.
A new study shows that targeted cancer drug selpercatinib can significantly reduce the risk of lung cancer returning in patients with a rare genetic subtype. After two years, 92% of patients remained cancer-free, compared to 61% who received a placebo.
A study from UC San Francisco researchers reveals that regulatory differences around the world are slowing the development and adoption of biosimilars. The lack of standardization in biosimilar approval processes is a major obstacle for these cheaper alternatives to expensive biologics, which could lower costs for patients.
A study published in the New England Journal of Medicine shows an investigational targeted therapy, daraxonrasib, significantly extends overall survival for patients with metastatic pancreatic cancer, reducing death risk by 60%, compared to standard chemotherapy.
The study demonstrated a response to treatment in several tumor types, including lung cancer and head and neck cancers. A significant tumor shrinkage was observed in four out of 14 patients treated within the optimal dose range.
A population-based screening trial evaluating a cell-free DNA multicancer early detection test found modest increases in diagnostic delay rates for head and neck, lung, and upper gastrointestinal cancers. These findings suggest that future trials may need to consider system-level spillover effects on healthcare resources.
A large international clinical trial led by UCL found that a gene test can safely spare many breast cancer patients of chemotherapy. The OPTIMA trial followed over 4,400 patients and suggested that those with hormone-sensitive breast cancer and low Prosigna scores can be treated safely with hormone therapy alone.
Two new international studies found that healthy lifestyles can have a protective effect on childhood cancer survivors, reducing the risk of chronic health problems. The studies suggest that physical activity, a healthy weight, and other lifestyle factors can significantly reduce the burden of disease in adulthood.
Researchers at the University of Jyväskylä have developed an AI model that can analyze colorectal cancer samples more efficiently and accurately predict the functioning of the cells' DNA repair mechanism. This could lead to shorter diagnosis times, reduced costs, and improved analysis accuracy.
Researchers at Columbia University Irving Medical Center have identified Sirtuin 1 as a key driver of neuroendocrine prostate cancer, an aggressive form of the disease. Genetic or pharmacological inhibition of Sirtuin 1 prevents tumor growth in mice and lays the groundwork for future clinical studies aimed at developing new treatments.
Three Salk faculty members, Sung Han, Daniel Hollern, and Graham McVicker, receive Keck Scholar-Fellow funding to investigate neural communication, immune tolerance in cancer, and gene expression regulation. The projects aim to advance high-risk, high-reward research and develop new technologies for targeted therapies.
A large national study found that veterans diagnosed with cancer are at a higher risk of suicide attempts, especially in the months following diagnosis. The risk can persist for years and is highest among younger veterans, women, and those with certain types of cancer.
Researchers aim to build a cohort of 2,000 AYA cancer survivors in NYC to study the short- and long-term effects of newer cancer treatments. The study will focus on challenges such as fertility and sexual health concerns, as well as financial stress.
The MIT researchers developed a new sensor that can detect biomarkers produced by bladder cancer cells in the bladder, allowing for earlier detection. This approach is nearly 50,000 times more sensitive than traditional urinalysis and can image tumor location in tissue.
Researchers developed a nanofiber drug delivery system that uses electrospun fiber membranes to deliver multiple drugs in concert, demonstrating improved efficacy against glioblastoma. The system enables localized long-term delivery of drugs directly at the tumor site after surgery.
Researchers from Ohio State University Comprehensive Cancer Center present new findings on a hospital program that redistributes unused oral cancer drugs donated by patients. The program helps patients avoid treatment delays caused by insurance issues, shipping problems or cost, and has been shown to reduce drug delays by six days.
Researchers discovered lung cancer cells change identity to resist treatment by reactivating a process involved in early lung development. This could help doctors predict which patients respond well to treatment and provide personalized care.
A comprehensive long-term study has demonstrated the efficacy of molecular blood tests in influencing leukemia course. The study found that early intervention based on molecular markers can have a significant impact on disease progression.
The National Comprehensive Cancer Network (NCCN) has launched a new free service providing weekly email updates on changes to evidence-based guidelines for cancer prevention, screening, treatment, and supportive care. The service aims to keep healthcare providers up-to-date with rapidly evolving evidence-based recommendations.
Research highlights the dual role of eosinophils in cancer, with higher counts associated with reduced risk and improved treatment response to immunotherapy. The immune-activating effects of eosinophils may help predict treatment outcomes and anticipate complications.
A study by Harvard T.H. Chan School of Public Health found that gut microbiome alterations persist even after adenoma removal, increasing the risk of colorectal cancer. The researchers discovered that diet and physical activity were closely tied to CRC-associated gut microbes, suggesting lifestyle habits may contribute to sustained risk.
The American Cancer Society has endorsed two new types of stool tests and recommends limiting the use of blood tests for colorectal cancer screening. The guidelines aim to encourage people to get screened while improving detection rates.
Researchers will present over 30 studies on precision oncology, early cancer detection and AI-powered personalized care. Featured topics include biomarker-driven treatments for bladder and lung cancers, new approaches for triple-negative breast cancer and AI-enabled analysis of tumor microenvironment in colon cancer.
Dr. Sharon Giordano and Dr. Eduardo Vilar-Sanchez receive ASCO Special Awards for their transformative work in breast cancer research and prevention, respectively. Their contributions advance understanding of cancer and improve patient outcomes.
Researchers at UC San Diego have identified a naturally occurring peptide that significantly slows melanoma growth, reduces tumor spread, and restores sensitivity in drug-resistant cells. The findings suggest CST could serve as the foundation for a new class of peptide-based therapies against advanced and therapy-resistant melanoma.
Researchers found that a vitamin D analog reduced fibroblast activation and increased T cell infiltration in pancreatic tumors, improving chemotherapy responses and progression-free survival. Patients with high vitamin D receptor expression also had longer overall survival.
A new AI model, MutationProjector, analyzes tumor DNA to predict immunotherapy and chemotherapy outcomes in various cancers. The model identifies biomarkers associated with treatment responses and provides insights into why predictions are made.
The PERCS initiative aims to develop and test interventions promoting comprehensive survivorship care for adult cancer survivors. Four randomized controlled trials will improve how primary care clinicians deliver survivorship care to over 18 million US cancer survivors.
Researchers found that smaller tetraploid cancer cells are more aggressive and tumorigenic, associated with worse prognosis and lower survival rates in several cancer types. This discovery challenges the conventional understanding of tetraploidy's role in cancer progression.
Researchers discover that kinases play a crucial role in moving cholesterol to activate a growth pathway in aggressive cancers. Without these enzymes, cancer cells are blocked from fueling tumor growth. The study highlights the importance of targeting lipid enzymes as a potential treatment strategy for cancers with TP53 mutations.
The Oncodarwinian Hypothesis proposes cancer as a potential immunoadaptive response, reframing uncontrolled division as an adaptive immune response. AI-based 3D printed p53 superproteins may accelerate tumor suppression and guide cancer treatment.
Researchers identified four distinct mutational clusters in oral cancers lacking traditional risk factors, with two linked to endogenous processes and unique driver gene mutations. The study suggests a potential role of the oral microbiome in tumor development and highlights opportunities for precision medicine approaches.
Researchers identified specific gene fusion patterns linked to more aggressive disease behavior and increased risk of metastasis in solitary fibrous tumors. The study suggests that these molecular differences could serve as potential biomarkers for predicting patient outcomes and guiding treatment decisions.
Researchers from Mass General Brigham Cancer Institute presented various studies on cancer treatments, including the efficacy of lung cancer drug neladalkib and a psychosocial digital app for patients with multiple myeloma. An electronic frailty index was also used to identify high-risk older adults receiving CAR-T cell therapy.